Doseology Sciences Inc.
Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of functional mushroom products with a focus on mental health research in Canada. The company also offers medicinal mushroom products, including tinctures. It sells its products online through doseology.com and e-commerce platforms, as well as through various retail chains and distribut… Read more
Doseology Sciences Inc. (DOSEF) - Total Assets
Latest total assets as of September 2025: $1.79 Million USD
Based on the latest financial reports, Doseology Sciences Inc. (DOSEF) holds total assets worth $1.79 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Doseology Sciences Inc. - Total Assets Trend (2020–2025)
This chart illustrates how Doseology Sciences Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Doseology Sciences Inc. - Asset Composition Analysis
Current Asset Composition (June 2025)
Doseology Sciences Inc.'s total assets of $1.79 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.8% |
| Accounts Receivable | $22.91K | 1.5% |
| Inventory | $17.04K | 1.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Doseology Sciences Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Doseology Sciences Inc.'s current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 95.8% of total assets in 2025, up from 29.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 1.5% of total assets.
Doseology Sciences Inc. Competitors by Total Assets
Key competitors of Doseology Sciences Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Doseology Sciences Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Doseology Sciences Inc. generates 0.03x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Doseology Sciences Inc. is currently not profitable relative to its asset base.
Doseology Sciences Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.51 | 13.01 | 1.82 |
| Quick Ratio | 12.86 | 12.60 | 1.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.34 Million | $ 961.03K | $ 2.25 Million |
Doseology Sciences Inc. - Advanced Valuation Insights
This section examines the relationship between Doseology Sciences Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.56 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 35.3% |
| Total Assets | $1.49 Million |
| Market Capitalization | $883.41 USD |
Valuation Analysis
Below Book Valuation: The market values Doseology Sciences Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Doseology Sciences Inc.'s assets grew by 35.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Doseology Sciences Inc. (2020–2025)
The table below shows the annual total assets of Doseology Sciences Inc. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $1.49 Million | +35.34% |
| 2024-06-30 | $1.10 Million | -21.20% |
| 2023-06-30 | $1.40 Million | -63.85% |
| 2022-06-30 | $3.87 Million | -35.41% |
| 2021-06-30 | $5.99 Million | +416.82% |
| 2020-06-30 | $1.16 Million | -- |